Geoff is the founder and Managing Partner of Digitalis. He currently represents Digitalis as a Director of CareDox and GRO Biosciences, and as a Board Observer of Second Genome.

Geoff is a co-founder and General Partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments.

Steve is a Partner at Digitalis. He currently represents Digitalis as a Director of Kenzen.

Steve is Chairman of the Board of Chromadex Corp. (Nasdaq: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food, beverage and cosmetic companies.

Drew is a Partner at Digitalis. He currently represents Digitalis as a Director of Somatix.

Previously Drew was the Head of New Ventures at Taylor Farms, the world’s largest processor of fresh-cut fruits and vegetables. During this time he led the creation and investment activity of Taylor Ventures, which invests in early-stage food and ag technology companies. 

Dac is the Technical Partner at Digitalis.

He received his Ph.D. in biophysics from the Icahn School of Medicine at Mount Sinai and an A.B. in physics from Harvard University.

Amit is a Principal at Digitalis. He currently represents Digitalis as a Director of Somatix.

Prior to Digitalis, Amit was at Mars, Inc. in both corporate strategy and corporate innovation roles.

Samuel is a Principal at Digitalis.

He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University. 

John is a Partner at Digitalis, investing the Companion Fund.  

Previously, John was with Delta Partners, a venture capital firm focusing on early-stage opportunities in the UK and Ireland.

Carlos Bustamante is a population geneticist whose research focuses on analyzing genome wide patterns of variation within and between species to address fundamental questions in biology, anthropology, and medicine.  

Dr. Brian Naughton was Founding Scientist and Vice President at 23andMe from its inception in 2006 until 2014. In this role, Naughton drew on his experience in bioinformatics, statistics and genetics to analyze data, develop algorithms and translate scientific research to drive the world's first Personal Genome Service. 

Dr. Nedwin has over 30 years of experience in the pharmaceutical and industrial biotechnology industries. He is an accomplished senior executive with domestic and international experience in new market identification, innovation, research & development, business planning, strategic positioning, operations, P&L, sales & marketing, involving both start-up, growth and billion dollar organizations.

John Wilbanks is the Chief Commons Officer at Sage Bionetworks and a Senior Fellow at Faster Cures. Previously, Wilbanks worked as a legislative aide to Congressman Fortney "Pete" Stark, served as the first assistant director at Harvard's Berkman Center for Internet & Society, founded and led to acquisition the bioinformatics company Incellico, Inc., and was executive director of the Science Commons project at Creative Commons.